AstraZeneca, EsoBiotec and cell therapy

AstraZeneca boosts cancer therapies push with $1 billion EsoBiotec buy
By Chandini Monnappa (Reuters) -Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, seeking to accelerate the development of its cell therapy capabilities,
AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio
The deal includes the Belgian biotech’s vivo cell-therapy platform, which modifies immune cells within the patient’s body, potentially increasing access to treatment and reducing costs.
AstraZeneca buys cell therapy biotech in up to $1bn deal
AstraZeneca has struck a deal to acquire biotechnology EsoBiotec for up to $1bn, as the London-listed pharmaceuticals group expands its investments in cell therapies for treating cancer.
AstraZeneca to buy EsoBiotec for up to $1 billion
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
AstraZeneca goes in vivo, penning $1B deal for Belgian off-the-shelf cell therapy biotech
AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all outstanding equity of the Belgian biotech for a total consideration of $1 billion—split between an upfront payment of $425 million and up to $575 million in developmental and regulatory milestones.
M&A News: AstraZeneca Seals Belgian Firm EsoBiotec Deal to Boost Cell Therapy
Healthcare giant AstraZeneca (AZN) is set to buy Belgian firm EsoBiotec for up to $1 billion. The deal aims to speed up progress in cell
AstraZeneca Seals Deal For EsoBiotec To Advance Cell Therapy: Details
AstraZeneca PLC has agreed to acquire EsoBiotec SA, a biotech company specializing in in vivo cell therapies. The $1 billion deal includes an initial payment of $425 million, with additional contingent consideration.
AstraZeneca paying up to $1bn for Belgian cancer company EsoBiotec
AstraZeneca, headquartered in Cambridge, could pay up to $1 billion on a cash and debt-free basis for Belgian company EsoBiotec to advance its cell therapy ambitions.
AstraZeneca to acquire EsoBiotec for $425M upfront
EsoBiotec announced it has entered into a definitive agreement to be acquired by AstraZeneca (AZN). The EsoBiotec Engineered NanoBody
Fierce Biotech1h
AstraZeneca's $800M rare disease bet hits primary phase 3 goal, but competitive strength still unclear
A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...
Eventful Monday For AstraZeneca - What's Going On?
AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for ...
AstraZeneca (AZN) Gets a Buy from UBS
UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £142.00. The ...
The Business Times5h
AstraZeneca to buy EsoBiotec for up to US$1 billion
CAMBRIDGE, UK] Drugmaker AstraZeneca said on Monday (Mar 17) it will buy biotechnology firm EsoBiotec for up to US$1 billion.
FTSE 100 Live 17 March: AstraZeneca unveils £1bn deal, Qinetiq cuts guidance
Phoenix shares surge on upgraded guidance 08:26 , Graeme Evans The FTSE 100-listed shares of ...
AstraZeneca announces Imfinzi approved in European Union
Imfinzi has been approved in the European Union as monotherapy for the treatment of adults with limited-stage small cell ...
Fierce Pharma3d
AstraZeneca embraces pickleball trend with Fasenra tour sponsorship, themed DTC ad
AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. | ...